On Demand Education
Updates in Screening and Surveillance for Barrett’s Esophagus
We have become excellent at treating Barrett’s esophagus (BE) related neoplasia. But to reduce the instance of esophageal adenocarcinoma (EAC) we need to increase the population under surveillance and leverage risk stratification tools to personalize the management of non-dysplastic BE.
Enhanced Metastatic Risk Assessment in Cutaneous Squamous Cell Carcinoma with the 40-Gene Expression Profile Test: An Interview with the Lead Author of DecisionDx-SCC’s Validation Study
Maui Derm DecisionDx-SCC Product Theater: Identifying the Risk of Metastasis in cSCC Patients with One or More Risk Factors
AHNS DecisionDx–SCC Webinar: Identifying the Risk of Metastasis in cSCC and cSCC-HN Patients
DermPath on Demand: Utility of Gene Expression Profiling in Melanocytic Lesions
Learn About Castle’s Comprehensive Diagnostic Offering
Our suite of highly accurate tests for melanocytic lesions of uncertain potential increases diagnostic confidence and enables better clinical management plans for patients. Learn the essentials from this comprehensive introduction by Matthew Goldberg, MD, Medical Director for Castle Biosciences.
DecisionDx-Melanoma: Predicting Individualized Risk of Recurrence
Castle Biosciences - Revolutionizing Gene Expression Profiling in Clinical Management of Dermatologic Cancers
Use of a Genomic-based Prognostic Tool to Inform Clinical Decisions for Patients with Cutaneous Melanoma
This activity is designed to address the following core and team competencies: Patient Care, Medical Knowledge, Practice-based learning and improvement, Interprofessional Collaboration, and Roles & Responsibilities.
CME/CE: (Credit Expiration Date: July 31st, 2021)
Incorporating Prognostic Gene Expression Profiling in the Management of Skin Cancer
Drs. Trotter and Sligh hosted a live Q&A session on the content discussed in this webinar. Register for free to be part of the webinar.
This activity has been developed to meet the educational needs of dermatologists, nurse practitioners, physician assistants, and staff who are dedicated to the management of patients with cutaneous melanoma and cutaneous squamous cell carcinoma
CME/CE: (1.0 AMA PRA Category 1 Credit(s))